as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹982.45
Change
-6.2 (-0.63%)
Open
₹988.9
Prev. Close
₹988.65
Day High
₹988.95
Day Low
₹974.0
Volume Analysis
Traded
28,685
Delivered
17,076
Delivery %
59.53%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (0)
No signal for this stock
Opportunities (3)
- •Strong 3-year EPS growth (16.3%)
- •Strong 3-year revenue growth (20.8%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,004.55 | ₹996.75 | ₹989.6 | ₹981.8 | ₹974.65 | ₹966.85 | ₹959.7 |
| Fibonacci | ₹996.75 | ₹991.04 | ₹987.51 | ₹981.8 | ₹976.09 | ₹972.56 | ₹966.85 |
| Camarilla | ₹986.56 | ₹985.19 | ₹983.82 | ₹981.8 | ₹981.08 | ₹979.71 | ₹978.34 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+22.55%
1 Week
-3.03%
1 Month
+11.48%
3 Months
-1.12%
6 Months
+24.37%
1 Year
+22.16%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹441.41
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
11.39%
Net margin 7.3% × asset turnover 1.0x × equity multiplier 1.56x
Company Overview
Sector
Healthcare
Market Cap
₹2,067 Cr
P/E (TTM)
31.1
ROE
12.2%
Book Value
₹275.0
Face Value
₹5.0
Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.
TopFund Analysis
Windlas Biotech Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 69/100. The strongest factor is Financial Strength (100/100), while Institutional Ownership (37/100) is the weakest area to weigh before deciding. Strong 3-year EPS growth (16.3%).
TopFund Score — Fundamentals Quality
69/100 — GoodData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- +Company has been maintaining a healthy dividend payout of 19.7%
- +Company's working capital requirements have reduced from 21.3 days to 14.4 days
- −Company has a low return on equity of 12.8% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Q2 & H1 FY27 Earnings Conference Call Transcript
Audio recording of October 30, 2026 analyst call for Q2 and H1 FY26 uploaded on website.
Windlas Biotech reported H1/Q2 FY27 results, crossed Rs.500 crore revenue, commercialized Plant-6, and secured EU GMP certification.
Approved Q2/H1 FY27 results; Ashok Kumar Windlass resigned as WTD/director, Hitesh Windlass appointed chairman on Nov 5, 2026.
Q2/H1 FY27 results approved; Ashok Kumar Windlass resigned as WTD; Hitesh Windlass appointed Chairman.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 141 | 145 | 153 | 162 | 171 | 175 | 187 | 195 | 203 | 210 | 222 | 233 | 238 |
| Expenses + | 124 | 128 | 134 | 142 | 149 | 154 | 164 | 170 | 177 | 184 | 194 | 209 | 213 |
| Operating Profit | 16 | 17 | 19 | 20 | 22 | 21 | 23 | 25 | 26 | 27 | 29 | 24 | 25 |
| OPM % | 12.0% | 12.0% | 12.0% | 13.0% | 13.0% | 12.0% | 12.0% | 13.0% | 13.0% | 13.0% | 13.0% | 10.0% | 11.0% |
| Other Income + | 2 | 3 | 3 | 3 | 4 | 4 | 5 | 4 | 5 | 5 | 4 | 5 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 4 | 3 | 3 | 3 | 4 | 6 | 6 | 7 | 8 | 7 | 8 | 8 | 8 |
| Profit before tax | 15 | 16 | 18 | 20 | 23 | 18 | 20 | 20 | 21 | 23 | 24 | 20 | 20 |
| Tax % | 24.0% | 26.0% | 23.0% | 24.0% | 25.0% | 26.0% | 23.0% | 23.0% | 22.0% | 24.0% | 25.0% | 25.0% | 21.0% |
| Net Profit + | 11 | 12 | 14 | 15 | 17 | 13 | 16 | 16 | 16 | 18 | 18 | 15 | 16 |
| EPS in Rs | 5 | 6 | 7 | 7 | 8 | 6 | 7 | 7 | 8 | 8 | 8 | 7 | 8 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 15 | 21 | 15 | 36 | 22 | 21 | 22 | 20 | 18 | 20 | 19 | 20 | 18 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 352 | 307 | 329 | 428 | 466 | 513 | 631 | 760 | 904 |
| Expenses + | 313 | 270 | 295 | 373 | 414 | 453 | 553 | 666 | 799 |
| Operating Profit | 39 | 38 | 34 | 55 | 52 | 60 | 78 | 94 | 105 |
| OPM % | 11.0% | 12.0% | 10.0% | 13.0% | 11.0% | 12.0% | 12.0% | 12.0% | 12.0% |
| Other Income + | 4 | 54 | 2 | -19 | 7 | 10 | 13 | 18 | 18 |
| Interest | 6 | 5 | 3 | 1 | 1 | 1 | 1 | 4 | 5 |
| Depreciation | 17 | 11 | 9 | 13 | 12 | 12 | 13 | 28 | 31 |
| Profit before tax | 20 | 76 | 25 | 22 | 46 | 57 | 77 | 80 | 87 |
| Tax % | 44.0% | 16.0% | 34.0% | 28.0% | 16.0% | 25.0% | 25.0% | 24.0% | 24.0% |
| Net Profit + | 11 | 64 | 16 | 16 | 38 | 43 | 58 | 61 | 66 |
| EPS in Rs | 7 | 35 | 9 | 9 | 17 | 20 | 28 | 29 | 31 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 20.0% | 20.0% | 20.0% | 20.0% | 20.0% |
| Sales growth | — | -13 | 7 | 30 | 9 | 10 | 23 | 20 | 19 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Reserves | 119 | 187 | 203 | 193 | 384 | 392 | 440 | 495 | 570 |
| Borrowings + | 57 | 32 | 29 | 32 | 7 | 5 | 4 | 33 | 35 |
| Other Liabilities + | 107 | 73 | 100 | 65 | 90 | 122 | 173 | 222 | 291 |
| Total Liabilities | 290 | 298 | 338 | 296 | 491 | 529 | 626 | 760 | 907 |
| Fixed Assets + | 86 | 64 | 70 | 96 | 91 | 109 | 179 | 223 | 213 |
| CWIP | 53 | 5 | 0 | 0 | 8 | 15 | 6 | 5 | 60 |
| Investments | 23 | 122 | 116 | 23 | 65 | 107 | 173 | 223 | 268 |
| Other Assets + | 128 | 107 | 152 | 177 | 327 | 298 | 268 | 308 | 366 |
| Total Assets | 290 | 298 | 338 | 296 | 491 | 529 | 626 | 760 | 907 |
| Equity Capital | 6 | 6 | 6 | 6 | 11 | 10 | 10 | 10 | 11 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 35 | 19 | 25 | 11 | 9 | 61 | 109 | 68 | 105 |
| Cash from Investing Activity + | -11 | -7 | -14 | -20 | -155 | -14 | -92 | -74 | -92 |
| Cash from Financing Activity + | -26 | -6 | -5 | 1 | 130 | -44 | -15 | 1 | -13 |
| Net Cash Flow | -2 | 6 | 5 | -8 | -15 | 3 | 2 | -5 | 0 |
| Free Cash Flow | 10 | 10 | 10 | 6 | -6 | -9 | 71 | 16 | 37 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 102 | 81 | 113 | 33 | 34 | 117 | 163 | 95 | 115 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 24.11% | 24.19% | 25.55% | 25.91% | 25.67% | 25.25% | 25.01% | 25.48% | 25.64% | 25.69% | 24.8% | 27.35% |
| Promoters | 62.82% | 62.82% | 62.51% | 62.51% | 62.51% | 62.34% | 62.34% | 61.98% | 61.98% | 61.9% | 63.31% | 63.31% |
| FII | 1.35% | 1.18% | 1.59% | 2.0% | 1.55% | 1.52% | 1.44% | 1.11% | 0.93% | 0.6% | 2.04% | 2.09% |
| DII | 11.71% | 11.82% | 10.35% | 9.58% | 10.26% | 10.89% | 11.22% | 11.44% | 11.44% | 11.8% | 9.84% | 7.24% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Windlas Biotech Limited (this stock) | 2,067 | 31.1 | 3.64 | 12.2% |
| Indoco Remedies Ltd. | 2,079 | — | 2.03 | -9.36% |
| Venus Remedies Limited | 2,002 | 16.4 | 2.84 | 15.6% |
| Hester Biosciences Ltd | 1,992 | 33.9 | 4.26 | 15.9% |
| Beta Drugs Limited | 1,990 | 38.3 | 4.54 | 18.8% |
| Panacea Biotec Ltd | 2,171 | — | 2.6 | -2.42% |
| Dishman Carbo Amcis Ltd | 2,183 | 151.0 | 0.33 | 1.58% |
Which Mutual Funds Hold Windlas Biotech Limited?
Frequently Asked Questions about Windlas Biotech Limited
Windlas Biotech Limited (WINDLAS) closed at ₹982.45 on NSE on 19 November 2026, down 6.2 (0.63%) from the previous close.
Windlas Biotech Limited trades on the NSE (National Stock Exchange of India) under the symbol WINDLAS.
Windlas Biotech Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 31.1.
Windlas Biotech Limited has a dividend yield of 0.63%.
Windlas Biotech Limited's 52-week high is ₹1,182.0 and its 52-week low is ₹697.0.
Windlas Biotech Limited has a market capitalisation of ₹2,067 crore.
Windlas Biotech Limited has a TopFund Quality Score of 69/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Windlas Biotech Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.